EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Trial of N -Acetyl- l -Leucine in Niemann–Pick Disease Type C

Tatiana Bremova-Ertl iD, Uma Ramaswami iD, Marion Brands iD, Tomas Foltan, Matthias Gautschi iD, Paul Gissen iD, Francesca Gowing, Andreas Hahn iD, Simon Jones, Richard Kay, Miriam Kolnikova iD, Laila Arash-Kaps und 10 weitere

New England Journal of Medicine · 2024-02 · 390 (5) · 421-431

DOI: 10.1056/nejmoa2310151 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2024-02. Verfasst von Tatiana Bremova-Ertl und 21 weiteren Autor:innen. Beteiligte Einrichtung: From University Hospital Bern, Bern, Switzerland (T.B.-E., M.G.); Royal Free London NHS Foundation Trust (U.R., F.G.), University College London (U.R…. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Central Nervous System Agents. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: IntraBio Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Niemann-Pick disease type C is a rare lysosomal storage disorder. We evaluated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, for the treatment of Niemann-Pick disease type C. METHODS: In this double-blind, placebo-controlled, crossover trial, we randomly assigned patients 4 years of age or older with genetically confirmed Niemann-Pick disease type C in a 1:1 ratio to receive NALL for 12 weeks, followed by placebo for 12 weeks, or to receive placebo for 12 weeks, followed by NALL for 12 weeks. NALL or matching placebo was administered orally two to three times per day, with patients 4 to 12 years of age receiving weight-based doses (2 to 4 g per day) and those 13 years of age or older receiving a dose of 4 g per day. The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status). Secondary end points included scores on the Clinical Global Impression of Improvement, the Spinocerebellar Ataxia Functional Index, and the Modified Disability Rating Scale. Crossover data from the two 12-week periods in each group were included in the comparisons of NALL with placebo. RESULTS: A total of 60 patients 5 to 67 years of age were enrolled. The mean baseline SARA total scores used in the primary analysis were 15.88 before receipt of the first dose of NALL (60 patients) and 15.68 before receipt of the first dose of placebo (59 patients; 1 patient never received placebo). The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Niemann-Pick Disease, Type CCentral Nervous System AgentsHumansData CollectionDouble-Blind MethodLeucineTreatment OutcomeCross-Over StudiesChild, PreschoolChildAdolescentYoung AdultAdultMiddle AgedAged

Substanzen

acetylleucineLeucineCentral Nervous System Agents

Autor:innen und Institutionen

  • From University Hospital Bern, Bern, Switzerland (T.B.-E., M.G.); Royal Free London NHS Foundation Trust (U.R., F.G.), University College London (U.R.), and Great Ormond Street Hospital, University College London (P.G.,…

ORCID-Profile: Tatiana Bremova-Ertl, Uma Ramaswami, Marion Brands, Matthias Gautschi, Paul Gissen, Andreas Hahn, Miriam Kolnikova, Thorsten Marquardt, Eugen Mengel, Julien H Park, Stella Reichmannová, Susanne A Schneider, Siyamini Sivananthan, Mark Walterfang, Pierre Wibawa, Michael Strupp, Kyriakos Martakis

Förderung

  • IntraBio Inc.

Zitieren

APA

Bremova-Ertl, T., Ramaswami, U., Brands, M., Foltan, T., Gautschi, M., Gissen, P., Gowing, F., Hahn, A., Jones, S., Kay, R., Kolnikova, M., Arash-Kaps, L., Marquardt, T., Mengel, E., Park, J. H., Reichmannová, S., Schneider, S. A., Sivananthan, S., Walterfang, M., …, & Martakis, K. (2024). Trial of N -Acetyl- l -Leucine in Niemann–Pick Disease Type C. New England Journal of Medicine, 390(5), 421-431. https://doi.org/10.1056/nejmoa2310151

Vancouver

Bremova-Ertl T, Ramaswami U, Brands M, Foltan T, Gautschi M, Gissen P, et al. Trial of N -Acetyl- l -Leucine in Niemann–Pick Disease Type C. New England Journal of Medicine. 2024;390(5):421-431. doi:10.1056/nejmoa2310151

BibTeX
@article{BremovaErtl2024,
  author = {Bremova-Ertl, Tatiana and Ramaswami, Uma and Brands, Marion and Foltan, Tomas and Gautschi, Matthias and Gissen, Paul and Gowing, Francesca and Hahn, Andreas and Jones, Simon and Kay, Richard and Kolnikova, Miriam and Arash-Kaps, Laila and Marquardt, Thorsten and Mengel, Eugen and Park, Julien H and Reichmannová, Stella and Schneider, Susanne A and Sivananthan, Siyamini and Walterfang, Mark and Wibawa, Pierre and Strupp, Michael and Martakis, Kyriakos},
  title = {Trial of N -Acetyl- l -Leucine in Niemann–Pick Disease Type C},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {5},
  pages = {421--431},
  doi = {10.1056/nejmoa2310151}
}
Kostenlos starten →